Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling

Kandice R. Levental,¹,¹⁰ Hongmei Yu,²,¹⁰ Laura Kass,² Johnathon N. Lakin,² Mikala Egeblad,⁴,¹¹ Janine T. Erler,³,¹² Sheri F.T. Fong,⁵ Katalin Csiszar,⁵ Amato Giaccia,³ Wolfgang Weninger,⁶ Mitsuo Yamauchi,⁷ David L. Gasser,⁸ and Valerie M. Weaver¹,²,⁴,⁹,*

¹Department of Bioengineering and Institute for Medicine and Engineering, University of Pennsylvania, Philadelphia, PA 19104, USA
²Center for Bioengineering and Tissue Regeneration, Department of Surgery, University of California, San Francisco, San Francisco, CA 94143, USA
³Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA
⁴Department of Anatomy, University of California, San Francisco, San Francisco, CA 94143, USA
⁵Cardiovascular Research Center, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI 96822, USA
⁶Immunology Program, Wistar Institute, Philadelphia, PA 19104, USA
⁷Dental Research Center, University of North Carolina, Chapel Hill, Chapel Hill, NC 27599, USA
⁸Department of Genetics, University of Pennsylvania, Philadelphia, PA 19104, USA
⁹Department of Bioengineering and Therapeutic Sciences, Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, and Helen Diller Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143, USA
¹⁰These authors contributed equally to this work
¹¹Present address: Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA
¹²Present address: Section of Cell and Molecular Biology, The Institute of Cancer Research, London SW3 6JB, UK
*Correspondence: valerie.weaver@ucsfmedctr.org
DOI 10.1016/j.cell.2009.10.027

SUMMARY
Tumors are characterized by extracellular matrix (ECM) remodeling and stiffening. The importance of ECM remodeling to cancer is appreciated; the relevance of stiffening is less clear. We found that breast tumorigenesis is accompanied by collagen crosslinking, ECM stiffening, and increased focal adhesions. Induction of collagen crosslinking stiffened the ECM, promoted focal adhesions, enhanced PI3 kinase (PI3K) activity, and induced the invasion of an oncogene-initiated epithelium. Inhibition of integrin signaling repressed the invasion of a premalignant epithelium, University of Pennsylvania, Philadelphia, PA 19104, USA

INTRODUCTION
The tumor stroma is characterized by extracellular matrix (ECM) remodeling and stiffening, and tissue stiffness has been exploited to detect cancer (Butcher et al., 2009; Sinkus et al., 2000). ECM stiffness enhances cell growth and survival and promotes migration (Lo et al., 2000), and ECM rigidity disrupts tissue morphogenesis by increasing cell tension (Paszek et al., 2005). Reduction of cell tension repressed the malignant behavior of mammary epithelial cells (MECs) and normalized the behavior of breast cancer cells in culture (Paszek et al., 2005). What drives ECM stiffening in tumors and whether ECM tension could drive tumor progression has yet to be determined.

Collagen is the most abundant ECM scaffolding protein in the stroma and contributes significantly to the tensile strength of tissue (Kolacna et al., 2007). Collagen metabolism is deregulated in cancer, where increased collagen expression, elevated deposition, altered organization, and enhanced matrix metalloproteinase (MMP) activity and collagen turnover have been implicated in tumor progression (Jodele et al., 2006). MMP-mediated collagen remodeling can create space for cells to migrate, produce substrate cleavage fragments with independent biological activity, modify adhesion to regulate tissue architecture, and activate, deactivate, or alter the activity of signaling molecules (Page-McCaw et al., 2007). Although high levels of MMPs correlate with poor prognosis in cancer patients (Tetu et al., 2006) and modulation of MMP activity changes tumor phenotype (Zheng et al., 2008), MMP inhibitors failed clinically (Coussens et al., 2002), indicating other ECM remodeling parameters regulate malignancy.

Type I collagen is considered a structural barrier against tumor invasion, but paradoxically, increased expression of collagen is associated with elevated incidence of metastasis (Ramassamy et al., 2003). Indeed, mammographic density, which is characterized by higher collagen I, increases breast cancer risk (Martin
and Boyd, 2008). Importantly, collagen crosslinking accompanies tissue fibrosis (van der Slot et al., 2005), and fibrosis increases risk of malignancy (Colpaert et al., 2003). Lysyl oxidase (LOX), a copper-dependent amine oxidase (Kagan and Li, 2003) that initiates the process of collagen crosslinking, is frequently elevated in tumors (Erler et al., 2009). Active LOX stiffens tissues and can compromise their function (Pfeiffer et al., 2005), and reduction of LOX activity tempers tissue stiffness and prevents fibrosis (Georges et al., 2007). Nevertheless, the relationship between collagen crosslinking, tissue fibrosis and tension, and cancer has yet to be assessed.

Integrins transduce cues from the ECM by assembling adhesion plaque complexes that initiate biochemical signaling and stimulate cytoskeletal remodeling to regulate cell behavior (Miranti and Brugge, 2002). Force increases integrin expression, activity, and focal adhesions (Paszek et al., 2005; Sawada et al., 2006). Human breast tumors are often fibrotic and stiff, and breast cancer cells that exhibit high tension have elevated integrins and focal adhesions and increased integrin signaling (Madan et al., 2006; Mitra and Schlaepfer, 2006). Thus, ECM stiffness could regulate malignancy by enhancing integrin-dependent mechanotransduction. Consistently, breast malignancy can be inhibited by genetically ablating integrin expression (White et al., 2004), and breast cancer cell behavior can be repressed by inhibition of integrin activity or reduction of cell tension (Paszek et al., 2005). Likewise, knockdown of the expression or inhibition of the function of focal adhesion kinase (FAK) or p130Cas, two integrin adhesion plaque proteins, impedes breast tumor progression (Cabodi et al., 2006; Lahlou et al., 2007). Here, we asked whether collagen crosslinking could stiffen the ECM and induce fibrosis to promote breast malignancy by altering integrins and whether inhibition of collagen crosslinking could prevent fibrosis and impede breast tumorigenesis by reducing integrin signaling.

RESULTS

ECM Stiffening and Collagen Crosslinking Accompany Breast Tumor Progression

The HER2 gene is a member of the epidermal growth factor receptor (EGFR) family that is amplified in 20%–25% of human breast cancers. The rat equivalent of HER2 is the wild-type Neu transgene, which, under the MMTV promoter (MMTV-Neu), develops breast tumors with a long latency (Kim and Muller, 1999). Using the MMTV-Neu model, we studied the relationship between tissue fibrosis, stiffness, and cancer. Unconfined compression and rheological testing showed an incremental stiffening of the mammary gland as it transitioned from normal to premalignant to invasive cancer (Figures 1A–1C, top) and demonstrated that the stromal tissue adjacent to the invading epithelium was also substantially stiffer than normal. Total levels (Figure S1 available online) and amount of fibrillar collagen increased markedly (Figures 1C and 1D), and second harmonics generation (SHG) imaging revealed the progressive linearization of the collagen adjacent to the developing epithelial lesions (Figures 1E and 1F).

We next explored whether collagen crosslinking could account for the dramatic ECM remodeling and stiffening. We noted an increase in levels of the major reducible bifunctional collagen crosslinks, dehydrodihydroxylysinonorleucine (DHLNL), and hydroxylysinonorleucine (HLNL) in the breast tumors, reflecting elevated crosslinked collagen (Figure 1G). We further detected increased amounts of the amine oxidase crosslinking enzyme, LOX, in the stromal cells of the premalignant Min foci and invasive tumors and in the invading transformed epithelium (Figure 1H).

These data establish an association between collagen crosslinking, LOX expression, ECM stiffness, and tissue fibrosis in Neu-induced breast tumorigenesis.

LOX-Mediated Collagen Crosslinking and Tissue Stiffening Promote Focal Adhesions and Tumor Progression In Vivo

We next asked whether LOX-mediated collagen crosslinking could stiffen the breast and promote invasion of a premalignant lesion. We used Ha-ras human MCF10AT MECs which upon injection into mice develop into premalignant tissues (Hu et al., 2008). We conditioned inguinal mammary fat pads of NOD/SCID mice, surgically cleared of their epithelium, with control fibroblasts or those expressing elevated LOX (Figures 2A, S2, and S3). Rheo-mechanical measurement revealed that the mammary glands conditioned with LOX expressing fibroblasts were stiffer (Figure 2B), picrosirius red staining showed that they had more fibrillar collagen (Figures 2C and 2D), and SHG imaging revealed that they had more linearized collagen (Figures 2C and 2E). Consistent with ECM stiffening, resident fibroblasts in the epithelial-cleared LOX-treated glands showed more FAKpY397 and p130Cas immunostaining, indicative of increased focal adhesions and mechanosignaling in the stromal cells (Figure 2C, bottom).

LOX preconditioning and stiffening of the mammary gland promoted the growth and invasion of Ha-ras premalignant...
Figure 2. Collagen Remodeling and Tissue Stiffening Promote Focal Adhesions and Tumor Invasion

(A) Experimental design.
(B) Scatter plot of breast rheology after LOX (FB.LOX) or control (FB.ctrl) fibroblast conditioning.
(C) Top two panels: photomicrographs of tissues described in (B) stained with picrosirius red and hematoxylin viewed under parallel and orthogonal polarizing filters. Scale bars represent 50 μm. Third panel: SHG images of tissues from fibroblast-conditioned mammary glands. The scale bar represents 25 μm. Fourth and fifth panels: confocal images of fibroblasts residing within fibroblast-conditioned mammary glands stained for active FAK (FAKpY397, red, fourth panel), p130Cas (red, fifth panel), and DAPI (nuclei, blue). The scale bar represents 50 μm.
(D) Scatter plot of fibrillar collagen in tissue shown in (C).
(E) Scatter plot of collagen linearity measured by curvature ratio from SHG images shown in (C).

894 Cell 139, 891–906, November 25, 2009 ©2009 Elsevier Inc.
mammary organoids injected into these tissues as revealed by a significant increase in lesion size and tumors that lacked margins (Figures 2F–2H). MECs in the LOX preconditioned glands also had more focal adhesions, as revealed by elevated FAK(Y397) (Figure 2H) and p130Cas (data not shown). To rule out any direct effect of LOX activity on MEC behavior, we also treated a cohort of animals in parallel (i.e., at time of MEC injection) with β-aminopropionitrile (BAPN), a natural and irreversible inhibitor of lysyl oxidase activity (Kagan and Li, 2003). Because BAPN treatment had no effect on tumor growth, invasion, and focal adhesions (Figures S4–S6), we concluded that it was LOX preconditioning of the stroma and ECM stiffness that promoted mammary tumor progression, and not any direct effect of LOX on the mammary epithelium. These findings demonstrate how ECM crosslinking and stiffening can induce focal adhesions and promote the growth and invasion of an oncogene-initiated mammary epithelium in vivo.

**Inhibition of LOX-Mediated Collagen Crosslinking Decreases Fibrosis and Reduces Focal Adhesions to Inhibit Breast Tumor Progression In Vivo**

We next asked whether reduction of LOX-dependent collagen crosslinking could temper tissue fibrosis and decrease focal adhesions, and whether this would inhibit breast tumor progression. We inhibited LOX activity using the cell-soluble BAPN (Lucero and Kagan, 2006) or a LOX-specific function-blocking polyclonal antibody that only inhibits extracellular LOX activity (Erler et al., 2006) and assayed collagen crosslinking, tissue fibrosis, focal adhesions, and breast tumor development.

Inhibition of LOX activity was initiated in five month old parous animals, when LOX levels were already increased in the stromal cells but were non-detectable in the mammary epithelium (Figure 1H). Treatment was continued for 1 month, after which the animals were allowed to recover for another month and then sacrificed (Figure 3A). At the time of sacrifice, the non-treated MMTV-Neu mice had high levels of active LOX in the serum, whereas BAPN or LOX-inhibitory polyclonal antibody-treated animals had reduced levels (Figure 3B). Mice with reduced LOX activity showed significant decreases in LOX-mediated collagen crosslinks, both reducible (DHLNL and HLNL) and nonreducible (pyridinoline) (Figures 3C and 3D), and the collagen fibrils adjacent to the epithelial lesions were less linear (Figures 3E and 3F). Consistent with the possibility that inhibition of collagen crosslinking prevented tissue fibrosis, LOX inhibition reduced fibrillar collagen (Figures 3G and 3H) and had less focal adhesions, as indicated by negligible FAK(Y397) (Figure 3I).

Inhibition of LOX activity also increased tumor latency (Figure 4A) and decreased tumor incidence (Figure 4B), despite ErbB2 activity (Figure 4C). Moreover, the palpable lesions formed in the LOX-inhibited animals were smaller (Figure 4D) and less proliferative (Figure 4E). LOX-inhibited mammary glands also stained positively for cytokeratin 14 along the basal periphery of the ducts, implying retention of their myoepithelium (Figures 4H and 4I). Hematoxylin and eosin (H&E) sections revealed that a significantly greater proportion of the lesions in the LOX-inhibited animals were hyperplastic or premalignant (hyperplastic alveolar nodules [HANs] or mammary intraepithelial neoplasias [MINs]) and the tumors that did develop were mostly low grade as opposed to the high grade carcinomas typically observed in the untreated Neu mice (Figures 4G and 4F). These results show how inhibition of LOX activity reduces collagen crosslinking, tempers tissue fibrosis, decreases focal adhesions, and impedes tumor progression to reduce breast tumor incidence.

**Collagen Crosslinking and ECM Stiffening Promote Focal Adhesions and Drive Invasion of Oncogenically Initiated Mammary Tissues in Culture**

We next assessed the effect of nonspecific induction of collagen crosslinking and stiffening on MEC invasion in the absence of fibroblasts, immune cells, and other stromal and systemic cellular and soluble factors (Figure 5A, experimental design). We explored the effect of nonspecific collagen crosslinking and stiffening on tumor invasion by adding ribose to the media of nonmalignant, MCF10A acini embedded in a 3D soft collagen I/reconstituted basement membrane gel (Col/rBM gel).

To determine whether MEC invasion required oncogenic signaling, we utilized MCF10As expressing an ErbB2 chimera (ErbB2.chim; called HER-2; the human homolog of Neu) consisting of the extracellular and transmembrane domains of low-affinity nerve growth factor receptor (p75NGFR), and the cytoplasmic kinase domain of ErbB2 linked to the synthetic ligand-binding domain from the FK506-binding protein (FKBP).

In these MECs, addition of the synthetic bivalent FKBP ligand, AP1510, drives homodimerization of ErbB2, activation of the kinase domain, and initiation of ErbB2 signaling (Muthuswamy et al., 2001). Chimeric ErbB2 signaling drives proliferation and luminal filling but fails to induce MEC invasion in rBM (Figure 5E). To study effects of homo- (ErbB2/ErbB2) and heterodimer (ErbB1/ErbB2) formation, we also engineered MECs in which the wild-type ErbB2 could be overexpressed through addition of doxycycline (ErbB2.TetOn; Figures S7 and S8).

In the absence of ErbB2 activity, MECs in collagen/rBM gels assembled acini, as illustrated by basally oriented β4 integrin and cell-cell localized beta catenin (Figure 5E). Glycation-mediated crosslinking stiffened the collagen (Figure 5B), increased colony size (Figure 5C), and disrupted tissue organization, as revealed by diffusely localized beta catenin and the appearance of random cells within the lumens (Figure 5E). MECs within the ribose crosslinked collagen gels also had elevated levels and co-localized β1 integrin and FAK(Y397), indicative of tension-induced...
Figure 3. Inhibition of Collagen Crosslinking Tempers Tissue Fibrosis and Reduces Focal Adhesions

(A) Experimental design.

(B) LOX enzymatic activity in serum of untreated (Control) compared to BAPN (+BAPN) or LOX-inhibitory antibody-treated (+LOX-Ab) Neu mice. Values are shown as mean ± SEM.

(C) Scatter plots of reducible collagen crosslinks in LOX-inhibited (LOX-Inhib) and untreated (Control) Neu breasts.

(D) Scatter plots of pyridinoline in LOX-inhibited (LOX-Inhib) and untreated (Control) Neu breasts.

(E) SHG images of mammary glands from BAPN-treated animals as described above. The scale bar represents 25 µm.

(F) Collagen curvature in SHG images from (D) (Supplemental Experimental Procedures). Data are mean ± SEM of three to five regions/four glands/condition.

(G) Photomicrographs of sections from control and BAPN-treated (LOX-Inhib) Neu mammary glands stained with picrosirius red and hematoxylin viewed under parallel or orthogonal polarizing filters. The scale bar represents 50 µm.

(H) Fibrillar collagen in control and LOX-inhibited glands from images shown in (F). Data are mean ± SEM of four to six images/four to eight glands/condition.

(I) Confocal images of sections from control and BAPN-treated Neu glands stained for active FAK (FAK<sup>Y397</sup>, red) and DAPI (nuclei, blue). The scale bar represents 50 µm.

*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
focal adhesions (Figure 5D). Nevertheless, in the absence of ErbB2 activity, ECM stiffening did not drive MEC invasion (Figures 5E and 5F).

Addition of either AP1510 (1 μM) or doxycycline (0.2 μg/mL) to the mammary acini, induced and activated (ErbB2.TetOn) or directly activated ErbB2 (ErbB2.chim) (Figure S9), promoted cell growth (data not shown), drove luminal filling, and destabilized cell-cell junctions, as revealed by diffusely localized beta catenin (Figure 5E). Sustained ErbB2 activation did not drive MEC invasion, as indicated by colony integrity and the retention of basally localized β4 integrin (Muthuswamy et al., 2001) (Figures 5E and 5F). Yet, when ErbB2 was activated in colonies in the crosslinked, stiffened gels, colony architecture disintegrated, as revealed by the absence of detectable beta catenin and disorganized β4 integrin staining, and MECs invaded into the gels (Figure 5E, white arrows; quantified in Figure 5F). SHG imaging revealed that individually, ErbB2 activation and ECM stiffening were accompanied by the appearance of prominent collagen bundles surrounding the colonies and showed that MECs with activated ErbB2 invaded on fibrils that extended perpendicularly into the crosslinked, stiffened gels (Figures 5E, white arrows highlight an invasive MEC, yellow arrows indicate collagen reorganization; Figure S9). These findings show how collagen crosslinking and ECM stiffening, per se, cooperate with oncogenes such as ErbB2 to promote the invasive behavior of a mammary epithelium.

Interestingly, confocal imaging revealed elevated β130Cas and FAK(Y397) staining that colocalized with β1 integrin (colocalization analysis of FAK(Y397) and β1 integrin; Pearson’s r = 0.78; β130Cas and β1 integrin, Pearson’s r = 0.89) in the stiffer breast tissue of the Neu mice (Figure 6A; see insert) and reduced levels of FAK(Y397) after LOX inhibition (Figure 3H). Moreover, inhibition of β1 integrin activity, with the function blocking antibody AIIB2, or reduction of integrin signaling by expression of an inducible FRNK (FRNK.TetOn; Figure S10) prevented the force-mediated invasion of the ErbB2 activated mammary organoids (Figures 5G and 5H). These findings show how ECM crosslinking and stiffness cooperate with an oncogene to promote breast cell invasion and implicate integrin signaling in force-dependent tumor progression.

**Integrin Clustering Promotes Focal Adhesions to Drive Invasion of a Ha-ras Mammary Epithelium In Vitro and In Vivo**

To determine whether integrin signaling would be sufficient to induce breast tumor invasion, we expressed a series of integrin constructs in nonmalignant MCF10A and Ha-ras premalignant MCF10AT MECs and assayed for invasive behavior in rBM and in vivo (Figure 6B).

Expression of the V737N integrin, which recapitulates tension-dependent integrin clustering, promoted focal adhesions, indicated by elevated FAK(Y397) (Figure 6C), and disrupted the integrity of mammary colonies in rBM, revealed by luminal filling and altered β4 integrin localization (Figure 6C, top). In contrast, expression of neither a wild-type (Figure 6C) nor a constitutively active β1 integrin (not shown; Paszek et al. [2005]) induced focal adhesions and disrupted mammary tissue architecture. Moreover, while the V737N β1 integrin mutant failed to promote invasion of the MCF10A MECs (Figure 6C), the V737N integrin induced the invasion of the Ha-ras premalignant MCF10AT colonies in rBM (Figures 6D and 6E). Upon injection into nude mice, the V737N integrin not only promoted focal adhesions and increased lesion size (Figure 6F), but also induced the invasive behavior of the Ha-ras MCF10AT organoids, as revealed by the loss of epithelial lesion margins and increased FAK(Y397) (see arrows in Figure 6G). These findings implicate tension-dependent integrin clustering and focal adhesions in breast tumor invasion. However, because integrin clustering could only promote invasion in Ha-ras premalignant MECs, they also illustrate how integrin-mediated mechanotransduction cooperates with oncogenic signaling to drive malignancy.

**Collagen Crosslinking and Tissue Stiffness Promote Integrin Clustering and Enhance PI3K Signaling to Regulate Invasion of a Premalignant Mammary Epithelium In Vitro and Tumor Progression In Vivo**

Integrins activate PI3K, and PI3K promotes invasion in culture and tumor progression in vivo (Webster et al., 1998). Therefore, we explored the relationship between focal adhesions and PI3K signaling in tension-dependent breast tumor invasion. We found Akt signaling, an established target of PI3K, to be elevated in the premalignant and malignant, rigid mammary tissue (Figure 7A) and in the mammary colonies in the ribose-stiffened collagen gels (Figure 7B).

We examined the effect of ECM rigidity on PI3K activity in MECs plated on rBM-functionalized polyacrylamide gels (rBM PA gel) with elastic moduli of 140–400 (soft) and >5000–10,000 (stiff) Pascals. These two extremes represent the ECM stiffness of healthy versus transformed breast tissue. Although substrate stiffness did not increase the levels of Akt(S473) in unstimulated MECs, ECM stiffness potentiated the magnitude of EGF-activated Akt(S473) (Figure 7C) and increased ErbB2-activated Akt(S473) (Figure 7D). MECs on soft gels that expressed the β1 integrin cluster mutant, but not the wild-type β1 integrin, also showed a significant increase in Akt(S473) activity after EGF stimulation. These results suggest that integrin mechanotransduction potentiates growth factor dependent PI3 kinase signaling (Figures 6B, 6C, and 7E).

Pharmacological inhibition of PI3K activity with LY294002 restored the colony architecture of ErbB2-activated MECs in ribose crosslinked collagen gels toward that of a noninvasive, polarized, cohesive colony (Figures 7F and 7G). Inhibition of PI3K activity reduced colony size, and immunostaining revealed that colonies treated with LY294002 retained β1 catenin at cell-cell junctions and had basally localized β4 integrin (Figure 7F). The epithelium from the LOX-inhibited Neu mice also had lower PI3K signaling, as revealed by fainter active Akt/PI3K substrate staining (Figure 7H). These data are consistent with a role for integrin mechanotransduction in PI3K-mediated breast tumor invasion. The findings suggest that ECM stiffness, as induced by elevated collagen crosslinking, could promote breast malignancy by enhancing integrin-GFR crosstalk (Figure 7I) (Miranti and Brugge, 2002).

**DISCUSSION**

Our findings identify collagen crosslinking as a critical regulator of desmoplasia and imply that the level and nature of ECM...
Figure 4. Inhibition of Crosslinking Reduces Tissue Fibrosis and Tumor Incidence and Enhances Tumor Latency

(A) Tumor latency.
(B) Tumor incidence without (Control) or with (LOX-Inhib) LOX inhibition.
(C) Confocal images of activate ErbB2 (ErbB2pY1248, red) in tissues from FVB nontransgenic littermates, Neu (MMTV-Neu) and LOX-inhibited mice (MMTV-Neu +LOX-Inhib). The scale bar represents 50 μm.
(D) Tumor size in control and LOX-inhibited mice.
(E) Confocal images of sections from LOX-inhibited and control glands stained for PCNA (red) and DAPI (nuclei, blue). The scale bar represents 50 μm.
(F) Grading of tumor lesions from mammary glands of control (n = 14) and BAPN-treated (LOX-Inhib, n = 13) animals.
(G) H&E-stained tissue showing typical normal glandular structure, hyperplastic alveolar nodules (HANs), and mammary intraepithelial neoplasias (MINs) premalignant lesions and grades I, II, and III ductal tumors.
crosslinks in a tissue could impact cancer risk and alter tumor behavior. The observations are consistent with links between ECM crosslinking and tissue stiffening in tissue fibrosis and could explain the increased risk to malignancy associated with these conditions (Colpaert et al., 2003). They might also explain why women with mammographically dense breasts have an increased relative risk of developing cancer (Martin and Boyd, 2008). Because aged tissues are stiffer and contain high levels of aberrant collagen crosslinks, the data offer a new paradigm for understanding why tumor incidence increases so dramatically with aging (Szauter et al., 2005).

Tissue fibrosis influences tumor progression by regulating soluble factors that induce inflammation and angiogenesis and stimulate cell growth and invasion (Bierie et al., 2009; Coussens et al., 1999). We showed that modification of the state of collagen crosslinking in ECM stiffness, two physical parameters of the tissue microenvironment, modulated the invasive behavior of an oncogene pre transformed mammary epithelium, even in the absence of cellular and soluble tissue and systemic factors. The findings imply that tissue fibrosis could regulate cancer behavior by influencing the biophysical properties of the micro-environment to alter force at the cell and/or tissue level. Importantly, we noted that focal adhesions were elevated in the stiffened breast tumors and organoid cultures, that forcing focal adhesions promoted MEC invasion, and that inhibiting focal adhesion signaling or tempering tissue stiffening reduced focal adhesions and tumor invasion. These observations are consistent with the notion that force regulates the invasive behavior of tumors by modulating integrin activity and focal adhesion assembly and signaling (Paszek et al., 2005). The findings thereby provide an explanation for why pYFAK and p130Cas are so often increased in breast tumors (Cabodi et al., 2006; Madan et al., 2006), even when integrin expression is frequently decreased (Koukoulis et al., 1993; Zutter et al., 1998). Indeed, the observations suggest that enhanced integrin signaling rather than just an increase in integrin expression is more critical for tumor progression.

Our data show how modulating the activity of one class of ECM crosslinking enzymes, the LOXs, can directly modify tumor progression by regulating collagen crosslinking and stiffness. The results are consistent with data indicating that LOX enzymes are elevated in many cancers (Erler and Weaver, 2009) and that LOX is induced by hypoxia inducible factor (HIF-1) and TGFβ, two key regulators of tumor behavior (Postovit et al., 2008). Indeed, cellular LOX promotes breast cell migration and invasion and enhances tumor proliferation and survival (Kirschmann et al., 2002). Hypoxia-induced LOX modulates tumor metastasis by regulating integrin function (Erler and Giaccia, 2006) by facilitating tumor extravasation (Bondareva et al., 2009) or by conditioning the metastatic niche (Erler et al., 2009). Our work indicates that LOX can promote tumor progression and MEC invasion by increasing fibrillar collagen and ECM stiffness. These observations are consistent with the major function of LOX in tissues as a key enzyme for collagen and elastin crosslinking that enhances tensile strength (Szauter et al., 2005). Consistently, by inhibiting LOX activity early, when levels were high in the stroma, we prevented ECM remodeling and stiffening and reduced tumor progression in the MMTV-Neu mice. Because a LOX-specific inhibitory polyclonal that cannot inhibit intracellular LOX also prevented fibrosis and tumor progression, our results suggest that LOX-mediated collagen crosslinking likely regulates breast tumor progression by modifying the tumor microenvironment rather than by directly changing cell behavior.

We observed that LOX inhibition reduced focal adhesions and PI3K signaling indicating that LOX modulates breast tumor progression by stiffening the ECM to drive focal adhesions assembly and enhance GFR-dependent PI3K signaling. Consistently, we showed that ribose-mediated collagen crosslinking, which induces nonspecific collagen glycation, also stiffened the ECM and enhanced focal adhesions and PI3K signaling to promote ErbB2-dependent breast tumor invasion. We noted that MEC invasion could be abrogated by inhibition of integrin and FAK activity, thereby illustrating the importance of ECM crosslinking and stiffness in tumor progression. This idea is consistent with our recent findings that LOX conditioning of the lung ECM promotes breast tumor metastasis (Erler et al., 2009) and data showing that fibrotic breast tumors have the poorest prognosis and highest rate of recurrence (Hasebe et al., 1997). Indeed, our findings underscore the notion that ECM crosslinking and stiffness, per se, is a key regulator of tumor progression. They imply that other ECM crosslinkers/modulators implicated in tissue fibrosis such as tissue transglutaminase, lysyl hydroxylase or some of the proteoglycans or even non-specific metabolic glycation end products (AGEs) might also similarly promote malignancy.

LOX has been proposed to be a tumor suppressor (Payne et al., 2007) possibly by directly inhibiting ECM adhesions and integrin signaling (Zhao et al., 2008). LOX-mediated ECM stiffening could also impede cell invasion in the absence of MMP activity (Zaman et al., 2006) reminiscent of highly crosslinked, stiff fibrotic tissues and scars that often never progress to malignancy. We noted that neither ECM stiffness nor forced integrin clustering induced mammary tissue invasion in the absence of oncogenic signaling. This suggests that other factors that modulate integrins and/or ECM remodeling or cellular tension likely cooperate with ECM crosslinking and force to promote tumor invasion (Katz et al., 2007; Wolf et al., 2007). Instead, ECM stiffness appears to operate as a signaling rheostat potentiating oncogenic cues to promote tumor invasion.

Cancer progression is accompanied by MMP-dependent ECM remodeling. Multiple MMPs are overexpressed in the tumor stroma, and some MMPs are upregulated in transformed epithelia (Jodele et al., 2006; Page-McCaw et al., 2007). Elevated expression of specific MMPs induced desmoplasia and malignant transformation (Sternlicht et al., 1999) and genetic ablation of MMPs or pharmaceutical inhibition of MMP activity reduced breast metastasis (Martin et al., 2008). These data argue that MMPs are critical for malignancy. Nevertheless, clinical trials with MMPs failed, suggesting that the role of MMPs in cancer

(H) Confocal images of breast tissue stained for cytokeratin 14 (red) and DAPI (nuclei, blue) in control and LOX-inhibited tissue. The scale bar represents 50 μm.

(I) Quantification of cytokeratin 14 positive glands in (H) detected in breast from control and LOX-inhibited animals. Values in (A), (B), (D), (F), and (I) are shown as mean ± SEM of four to six measurements/four to 12 tissue sections/group. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
is more complicated (Coussens et al., 2002). Indeed, MMPs collaborate with crosslinking enzymes such as LOX to facilitate collagen maturation, and MMPs and LOX regulate the expression and activity of soluble factors such as transforming growth factor beta (TGFβ) that regulate tumor cell behavior (Atsawasawan et al., 2008; Csiszar, 2001; Decitre et al., 1998; Szauder et al., 2005). TGFβ in turn regulates the expression of many ECM proteins and modifying enzymes including LOXs, and TGFβ increases levels of factors that evoke inflammation, induce fibrosis and promote metastasis (Bierie and Moses, 2006; Oleggini et al., 2007). Indeed, force itself modulates TGFβ activation and compression alters growth factor signaling (Tschumperlin et al., 2004; Wipff et al., 2007). These findings underscore the dynamic and reciprocal relationship between ECM deposition, processing, degradation, and force. They suggest that cancer is best viewed as a dynamic, phenotypically plastic, and highly coordinated tissue remodeling process that is tightly regulated by biochemical and mechanical cues. Accordingly, not only will we need to clarify the role of ECM cleavage in tumors but we will also be obliged to understand how ECM remodeling is integrated within the context of its deposition, posttranslational modifications, and topological rearrangement and to take into consideration the effect of mechanical force as a key regulator of malignancy.

**EXPERIMENTAL PROCEDURES**

**Antibodies and Reagents**

Antibodies were as follows: i4 integrin (SE1); i1 integrin (Alibi2, Chemicon); FAK (77), YES (1), E-Cadherin (610405, BD Transduction); laminin-5 (BM165, MP Marinkovich); i2 actin (AC-15, Sigma); ErbB2 (3B5, Calbiochem); polyclonal i2 catenin (Sigma); FAK17397 (BioSource); Phospho-Ser/Thr) Akt Substrates and Akt1176 (Cell Signalling); Akt (BD Pharmingen); p130Cas, ErbB21248 (Abcam); cytoskeleton 14 (Covance); LOX (A. Giaccia, Stanford University); LOX polyclonal activity inhibitory antibody (OpenBiosystems); and secondary AlexaFluor goat anti-mouse, anti-rabbit, and anti-rat (488 and 555 conjugates), AlexaFluor phalloidin (488 conjugate, Invitrogen); and sheep anti-mouse and anti-rabbit HRP-linked (Amersham). Reagents included LY294002 (50 mm in DMSO, Calbiochem).

**Cell Manipulations**

MEC and fibroblast cell lines were cultured as described (Paszek et al., 2005). Collagen crosslinking was induced by addition of 15 mM ribose to the culture medium (Girton et al., 1999). iBM-conjugated PA gels with calibrated stiffness were prepared as described (Johnson et al., 2007).

**Vector Constructs and Gene Expression**

Full-length human ErbB2 (K. Ignatowski) was cloned into the pRep retro Tet IRES EGFP tetracycline-inducible vector. The i1 integrin wild-type, i1 integrin glycine wedge constitutively active, and i1 integrin clustering mutant V737N constructs and the preparation of virus and cell infection and selection have been described (Paszek et al., 2005). Four myc tags were added to the C terminus of full-length LOX and cloned into the pLV puro TetO/CMV tetracycline-inducible lentiviral vector and expressed bicistronically with eGFP.

**Elastic Modulus Measurements**

Mammary glands and gels were assayed for materials properties by uncon fined compression and rheometrical analysis (Paszek et al., 2005) (Supplemental Experimental Procedures).

**Mice and Treatments**

FVB-TgN MMTV-Neu, NOD/SCID, and BalBc nu/nu mice (Jackson Laboratory) were maintained in accordance with University of Pennsylvania and University of California Institutional Animal Care and Use Committee guidelines. For LOX-inhibitory studies, animals were treated with BAPN (3 mg/kg; Spectrum) in the drinking water (four to eight mice/group, four studies) or a LOX function-blocking polyclonal antibody (3 mg/kg; OpenBiosystems, D8746) injected intraperitoneally twice per week (three to four mice/group, one study). Mice were sacrificed at 7–7.5 months of age, at which time tail vein blood was collected. Lesions were detected by palpation (~3 mm diameter), and tumor volume was assessed with calipers. At sacrifice mammary glands were excised, imaged, and mechanically tested or snap frozen or paraformaldehyde fixed.

**Tumor Grading**

Tumor grading was performed blinded on H&E-stained sections from untreated (n = 14) or BAPN-treated (n = 13) #2–3 mammary glands. Premalignant lesions were defined as HAN- or MIN-like foci. Grade I lesions were well defined as homogenous carcinomas, grade II contained areas with strong necrosis, stromal reaction and/or red blood cells outside of tumor blood vessels, and grade III also contained necrosis and nuclear pleomorphism. Adja cent tissue was defined as mammary tissue surrounding a tumor that was cut away from the tumor prior to subsequent analysis. A small set of anti-LOX-treated mice (n = 4) was compared with their controls (n = 3), and showed they the same tendency to less progressed lesions as was observed in the BAPN-treated animals.

**Xenograft Manipulations**

NOD/SCID mice (n = 24) were used for mammary fat pad transplantation studies (Kuperwasser et al., 2004). In brief, the rudimentary inguinal epithelium was removed from 3-week-old anesthetized female mice and 5 × 10^9 NIH 3T3 WT or LOX-expressing fibroblasts (2.5 × 10^6 were treated with 4Gy irradiation 24 hr prior to injection) were injected into the left and right mammary glands. Two weeks after fibroblast injection, 1 × 10^6 DCIS.com MCF10AT MEC 4-day-old rBM-generated, proliferating organoids (16–20 cells/organoid) were suspended in Dulbecco’s modified PBS and injected into the preconditioned mammary fat pads (n = 24).
Figure 6. β1 Integrin Clustering Promotes Focal Adhesions and Drives Invasion of a Premalignant Mammary Epithelium in Culture and In Vivo

(A) Combined and split (inserts) confocal images of tissue sections from MMTV-Neu breast stained for DAPI (nuclei, blue) and p130Cas (red, top), or β1 integrin (green, bottom) and activate FAK (FAKpY397, red). The scale bar represents 20 μm. (Colocalization analysis of the malignant tumors: FAKpY397 and β1 integrin, Pearson’s r = 0.78; p130Cas and β1 integrin, Pearson’s r = 0.89.)

(B) β1 integrin constructs used for the studies shown in (C)–(G).

(C) Confocal images of MCF10A MEC rBM colonies expressing the β1 integrin wild-type [β1(WT)] or clustering mutant [β1(V737N)] stained for β4 integrin (red, top), active FAK (FAKpY397, red, bottom) and DAPI (nuclei, blue).

(E) Ha-ras MEC

F: Ha-ras MEC

G: Ha-ras MEC
fat pads. All mice were sacrificed at 8 weeks of age (3 weeks after MEC injection and 5 weeks after fibroblast injection), lesion volume was assessed by caliper measurement, photographed in situ, and dissected gland fragments were imaged and mechanically tested or snap frozen, or fixed and paraffin embedded.

**Subcutaneous Studies**

Proliferating rBM-generated organoids (16–20 cells/organoid) from each experimental condition were injected subcutaneously into the rear flanks of BalbC nu/nu mice (six to eight mice/group; 5–10 × 10^4), tumor formation was monitored for 3 weeks, and samples were assessed as above at study termination.

**Collagen Crosslinking**

Mammary gland collagen was reduced with standardized NaB^3H_4_, hydrolyzed with 6N HCl, and subjected to amino acid and collagen crosslink analyses as described (Yamauchi and Shibira, 2008) (Supplemental Experimental Procedures). The reducible crosslinks, dehydro-dihydroxylysinoonorleucine (deH-DHNLL) and deH-dihydroxylysinoonorleucine (deH-HNHL), their ketamiones, were identified as their reduced forms, i.e., DHNLN and HNHLN. The crosslinks analyzed (reducible and nonreducible) were quantified as moles/mole of collagen based on the hydroxyproline value of 300 residues per collagen molecule. LOX activity was measured in cell supernatant and plasma as described (Erler et al., 2006).

**Immunostaining and Imaging**

Immunofluorescence and imaging of 3D cultures and tissues was as described (Paszek et al., 2005). Picrosirius red analysis was achieved through the use of paraffin sections of mammary glands stained with 0.1% picrosirius red (Direct Red 80, Sigma) and counterstained with Weigert’s hematoxylin to reveal fibrillar collagen. Sections were serially imaged with an Olympus IX81 fluorescence microscope fitted with an analyzer (J-ANT) and polarizer (J-POT, Olympus) oriented parallel and orthogonal to each other and quantified with minimal thresholding. Two-photon second harmonics imaging was performed on a Prairie Technology Ultima System attached to an Olympus BX-51 with a water immersion objective, and samples were quantified by calculation of the linearity of multiple collagen fibrils (see the Supplemental Data for further details).

**Immunoblot Analysis**

Cells were lysed in RIPA or Laemmli buffer and assayed by immunoblotting (Johnson et al., 2007).

**Statistics**

Statistical analysis was performed with GraphPad Prism with an unpaired student’s t test, two-way ANOVA, or Fisher’s exact test.

**SUPPLEMENTAL DATA**

Supplemental Data include Supplemental Experimental Procedures and 11 figures and can be found with this article online at http://www.cell.com/supplemental/S0092-8674(09)01353-1.

**ACKNOWLEDGMENTS**

We thank K. Ignatowski for the ErbB2 construct, M.P. Marinkovich for the BM165 antibody; P. Mass for two-photon microscopy guidance, and R.G. Wells for mentoring of K.R.L. The work was supported by grants NIH R01-CA078731, DOD W81XWH-05-1-330, DOE A107165, CIRM RS1-00449, and NCI U54CA143836 to V.M.W. NIH T32HL00795404 supported K.R.L., and NIH R01-CA057621 supported M.E.

Received: January 8, 2009

Revised: July 14, 2009

Accepted: September 28, 2009

Published online: November 19, 2009

**REFERENCES**


A  MMTV-neu  
Tissue Stiffness

Normal  Premalignant  Tumor

Activated Akt Substrates
DAPI

80 μm

B

Control  +Ribose

Activated Akt Substrates
DAPI

80 μm

C

EGF (min)
Akt

soft  stiff

0 5 15 30 60

0 5 15 30 60

Relative Akt (a.u.)

0 1 2 3 4 5

0 15 30 45 60

EGF pulse (min)

D

Normalized Akt phosphorylation

soft  stiff

-ErbB2  +ErbB2

0.0 2.5 5.0 7.5

0 15 30 45 60

E

Relative Akt phosphorylation (a.u.)

0 1 2 3 4 5

0 15 30 45 60

EGF Pulse

F

+Vehicle  +Ly294002

Control  +Ribose  +ErbB2

Activated Akt Substrates
DAPI

20 μm

G

MCF10A + ErbB2

% Invasive Colonies

Ly294002

Control  +Ribose

H

Control  LOX-Inhib

Activated Akt Substrates
DAPI

50 μm

I

Normal  Premalignant  Tumor

Membranous epithelial cell
Fibroblast
Myofibroblast
Mammary epithelial cell
Basement membrane

904  Cell 139, 891–906, November 25, 2009 ©2009 Elsevier Inc.


